Shares of Israel's Teva Pharmaceuticals slid after the company announced that a late-stage trial of a higher dose of its MS drug Copaxone did not perform better than a standard dose. Report [1]
Links:
[1] http://money.cnn.com/news/newsfeeds/articles/apwire/ef280dda1755322a30e682d36cc05a12.htm